Lundbeck starts roll-out of bipolar drug Sycrest in Denmark

6 April 2011

Danish drugmaker H Lundbeck A/S (LUN.CO: DC) has started the roll out of Sycrest (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults in Europe, with Denmark being the first country to launch.

Sycrest was licensed from Merck & Co (NYSE: MRK) in October 2010, and Lundbeck was granted exclusive commercial rights in all markets outside the USA, Japan and China. On September 1 2010, Sycrest received European Union approval from the European Medicines Agency (EMA) based on clinical data showing significant remission (versus placebo) in bipolar patients with manic and mixed episodes. Merck has already launched asenapine in the USA under the brand name Saphris.

Sales of $759-$949 million projected

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK